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KDOQI practice guidelines recommend predialysis blood
pressure o140/90mmHg; however, most prior studies had
found elevated mortality with low, not high, systolic blood
pressure. This is possibly due to unmeasured confounders
affecting systolic blood pressure and mortality. To lessen this
bias, we analyzed 24,525 patients by Cox regression models
adjusted for patient and facility characteristics. Compared
with predialysis systolic blood pressure of 130–159mmHg,
mortality was 13% higher in facilities with 20% more patients
at systolic blood pressure of 110–129mmHg and 16% higher
in facilities with 20% more patients at systolic blood pressure
of X160mmHg. For patient-level systolic blood pressure,
mortality was elevated at low (o130mmHg), not high
(X180mmHg), systolic blood pressure. For predialysis
diastolic blood pressure, mortality was lowest at
60–99mmHg, a wide range implying less chance to improve
outcomes. Higher mortality at systolic blood pressure of
o130mmHg is consistent with prior studies and may be due
to excessive blood pressure lowering during dialysis. The
lowest risk facility systolic blood pressure of 130–159mmHg
indicates this range may be optimal, but may have been
influenced by unmeasured facility practices. While additional
study is needed, our findings contrast with KDOQI blood
pressure targets, and provide guidance on optimal blood
pressure range in the absence of definitive clinical trial data.
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Hypertension (HTN) is a leading cause of mortality world-
wide.1,2 Based on large clinical outcomes trials, clinical practice
guidelines recommend treatment to blood pressure (BP)
o140/90 mm Hg in most patients with HTN and o130/
80 mm Hg in patients with diabetes or chronic kidney disease.3
Patients with end-stage renal disease (ESRD) treated by
dialysis have an increased risk of mortality, with nearly 50%
of deaths due to cardiovascular (CV) causes.4,5 The burden
of ESRD is rising internationally, with prevalence of ESRD
treated by dialysis exceeding 350,000 in the United States.4,6
Because the prevalence of HTN among maintenance dialysis
patients is 60–90%,5,7 its treatment is considered an
important means to improve outcomes. The 2005 National
Kidney Foundation Kidney Disease Outcomes Quality
Initiative (KDOQI) clinical practice guideline recommends
pre- and postdialysis BP goals of o140/90 and 130/
80 mm Hg, based in part on data in the nondialysis
population. A direct relation between treatment of elevated
BP levels and improved outcomes among dialysis patients has
not been demonstrated, and definitive clinical trials investi-
gating optimal target BP have yet to be carried out.
Observational studies consistently have found elevated
mortality in patients with low, but not high, BP levels.5,8–13
Some have speculated that the explanation for the
observed relation between lower BP and elevated mortality
is that hemodialysis (HD) patients have serious coexisting
illnesses (for example, poor ventricular function) that lower
BP and increase mortality risk (that is, association of lower
BP with elevated mortality is confounded by poor health
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status).5 Because observational analyses of BP and clinical
outcomes are subject to bias due to unmeasured patient
characteristics affecting BP and health status (that is,
unmeasured confounders), an objective of the study was to
lessen this bias using analysis of BP management practices
at the dialysis facility level, relating patient-level survival to
the fraction of patients in each BP category at each dialysis
facility. Analyses of patient-level BP are also presented. A goal
of the study was to identify the optimal range of achieved BP
for most of the patients in an HD unit, directly informing
treatment decisions in routine clinical practice.
RESULTS
Among 24,525 patients, total patient years of follow-up were
42,174, number of deaths was 5849, and mortality rate was
0.14 per year.
Distributions of predialysis BP and patient characteristics by
predialysis SBP
Figures 1a and 2a show distribution of predialysis systolic
blood pressure (SBP) and diastolic blood pressure (DBP) by
region. Among all study participants, mean SBP was
147±24 mm Hg; mean DBP was 77±14 mm Hg. By region,
Europe and Australia/New Zealand had lower average BP
levels. Figures 1b and 2b show facility-level predialysis SBP
and DBP distribution, demonstrating substantial variation
between facilities. Table 1 shows distributions of selected
baseline patient characteristics by patient-level SBP, demon-
strating generally unbalanced distributions of measured
variables across SBP categories. Large variations in patient
characteristics across patient-level SBP categories were also
found within each region. When patients were categorized
according to facility-level SBP (by quartiles, based on percent
of facility having patients with SBP X160 mm Hg) within
each region, the majority of patient characteristics were
balanced (Supplementary Table A online).
All-cause mortality by predialysis SBP categories (patient
level and facility level)
Figure 3a and b shows results of fully adjusted multivariable
models. Compared with the reference category of
130–139 mm Hg, all-cause mortality was elevated for patients
with SBP 110–119 mm Hg (hazard ratio (HR)¼ 1.14, 95%
confidence interval (CI)¼ 1.01–1.28, P¼ 0.03) and
120–129 mm Hg (HR¼ 1.11, 95% CI¼ 1.00–1.23, P¼ 0.04),
and lower for patients with SBP 150–159 mm Hg (HR¼ 0.90,
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Figure 1 |Predialysis systolic blood pressure (SBP)
distribution. (a) Distribution of patient-level predialysis SBP (by
region). (b) Distribution of facility-level predialysis SBP (overall). A
total of 25,907 hemodialysis patients from 922 facilities in Dialysis
Outcomes and Practice Patterns Study (DOPPS) I–III with end-
stage renal disease duration of4180 days. Europe/Australia/New
Zealand (Europe/ANZ) includes France, Germany, Italy, Spain,
United Kingdom, Belgium, Sweden, Australia, and New Zealand.
North America includes United States and Canada. The mean (s.d.)
of predialysis SBP in Europe/ANZ, North America, and Japan was
141 (24), 151 (24), and 151 (22) mmHg, respectively.
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Figure 2 |Predialysis diastolic blood pressure (DBP)
distribution. (a) Distribution of patient-level predialysis DBP (by
region). (b) Distribution of facility-level predialysis DBP (overall). A
total of 25,836 hemodialysis patients from 921 facilities in Dialysis
Outcomes and Practice Patterns Study (DOPPS) I–III with end-
stage renal disease duration of4180 days. For abbreviations, see
footnote of Figure 1. The mean (s.d.) of predialysis DBP in Europe/
ANZ, North America, and Japan was 76 (14), 79 (15), and 79 (13)
mmHg, respectively.
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95% CI¼ 0.81–0.99, P¼ 0.03). For patients with SBP
X160 mm Hg, there was no consistent difference in mortality
from the reference category. Analyses of facility-level SBP
categories (6 continuous variables, representing the proportion
of facility patients in each SBP category except 130–139 mm Hg)
showed elevated mortality consistently across low and high SBP
categories. Combining categories based on results in Figure 3b,
for facilities with 20% more patients in categories other
than 130–159 mm Hg, higher mortality was observed for
110–129 mm Hg (HR¼ 1.13, 95% CI¼ 1.05–1.21, P¼ 0.001)
andX160 mm Hg (HR¼ 1.16, 95% CI¼ 1.10–1.23, Po0.001).
As corroborative data, Supplementary Table B online shows
generally lower crude mortality rates among facilities with more
patients in the SBP 130–159 mm Hg range. The result of
instrumental variable analysis also indicated a U-shape
association between SBP and mortality, with elevated hazards
at o130 and X150 mm Hg (Supplementary Table C online).
As a sensitivity analysis, we examined the association of SBP
with all-cause mortality among all patients, including those with
SBP o110 mm Hg (n¼ 25,907). As expected, in patient-based
analysis, the HR for SBP o110 mm Hg was elevated
(HR¼ 1.55, 95% CI¼ 1.39–1.71, po0.001), compared with
130–139 mm Hg. Facility-level analyses were corroborative:
patients in facilities with 20% more patients with SBP
o110 mm Hg versus the reference group (130–159 mm Hg)
had a 27% higher mortality rate (HR¼ 1.27, 95%
CI¼ 1.13–1.41, Po0.001). An additional analysis based on
most recent SBP level, rather than median of three values,
yielded similar findings. Comparable results were obtained when
missing data were calculated by multiple imputation, with point
estimates varying o2% and P-values not appreciably altered.
Predialysis DBP
Mortality risk was lowest at 60–99 mm Hg in fully adjusted
patient- and facility-level models (Figure 4a and b). Fewer
patients had DBP outside the range of 60–99 mm Hg (14%)
than outside the lowest risk SBP range of 130–159 mm Hg
(53%; Figures 1a and 2a).
Table 1 | Baseline patient characteristics (means or proportions) by category of patient SBP at baseline
Patient SBP categories
o110mmHg 110–129mmHg 130–159mmHg X160mmHg
Characteristic (mean or %) (n=1370) (n=4209) (n=12,139) (n=8188) P-value*
SBP (mmHg) 98 120 144 174 —
Demographics
Age (years) 63.2 62.2 61.3 61.1 0.31
Body mass index 24.1 24.5 24.4 24.3 0.08
Black race (overall) 9% 9% 12% 16% o0.0001
Black race (USA only) 8% 8 11% 15% o0.0001
Male 54% 55% 58% 58% 0.01
Years with ESRD 7.1 5.6 5.3 5.0 o0.0001
Education (above high school) 47% 48% 51% 51% o0.0001
Income (above $20,000 or equivalent) 32% 33% 33% 30% 0.02
Coexisting conditions
Coronary heart disease 50% 47% 44% 45% 0.51
Cancer 14% 13% 11% 9% 0.0004
Other cardiovascular disease 50% 41% 36% 33% o0.0001
Cerebrovascular disease 17% 16% 16% 18% o0.0001
Congestive heart failure 41% 35% 31% 34% 0.0004
Diabetes mellitus 24% 27% 33% 44% o0.0001
Gastrointestinal bleed in past 12 months 7% 6% 6% 6% 0.68
HIV/AIDS 0.5% 0.5% 0.9% 0.9% 0.17
Lung disease 15% 13% 11% 10% 0.01
Neurological disorders 14% 11% 10% 10% 0.89
Psychiatric disorder 20% 18% 17% 16% 0.18
Peripheral vascular disease 29% 25% 25% 26% o0.0001
Recurrent cellulitis/gangrene 11% 8% 8% 8% 0.07
Labs and dialysis variables
Hemoglobin (g/dl) 11.3 11.3 11.1 10.9 0.0014
Serum PTH (pg/ml) 281 274 277 282 0.12
Serum phosphorus (mg/dl) 5.4 5.4 5.6 5.7 o0.0001
Serum albumin (g/dl) 3.6 3.7 3.8 3.8 o0.0001
Serum ferritin (ng/ml) 481 443 422 405 0.92
Serum creatinine (mg/dl) 8.8 9.2 9.5 9.8 0.0048
Use of catheter (%) 21% 17% 13% 13% 0.0006
Single-pool Kt/V 1.49 1.46 1.44 1.42 o0.0001
Number of antihypertensive medications 0.6 0.8 1.2 1.6 o0.0001
Abbreviations: ESRD, end-stage renal disease; PTH, parathyroid hormone; SBP, systolic blood pressure.
A total of 25,907 HD patients from 922 facilities in Dialysis Outcomes and Practice Patterns Study (DOPPS) I–III (all countries) with ESRD duration of4180 days. *P-values were
obtained from separate linear mixed or logistic models with each patient characteristic as outcome and a categorical variable of blood pressure category as predictor,
adjusting for geographic region and study phase and accounting for facility-clustering effects, to test for difference in each patient characteristic (mean or percent) across
three SBP categories (excluding SBP o110mmHg (shaded; see text for details)).
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Influence of covariate adjustment
Figures 5a and b and 6a and b show the influence of
progressively more comprehensive adjustment on the
associations of predialysis BP with survival. For patient-level
SBP, the associations were modestly attenuated (brought
toward null) at higher BP, with adjustment for demographics,
comorbidities, and laboratory values. Estimates for DBP were
substantially attenuated by adjustment for demographics
(mainly age), and were altered to a smaller extent by
adjustment for comorbidities and lab values. At high DBP,
progressive adjustment reversed direction of the association,
from lower-to-higher mortality. As additional sensitivity
analyses, adjustment for education level, household income,
and antihypertensive agents had very little influence on the
estimates presented herein. Antihypertensive agents were
analyzed in three different ways: (1) any use (yes/no), (2)
number of antihypertensive agents, and (3) separate dummy
variables for seven classes of antihypertensive medications
(yes/no for: angiotensin receptor blockers, angiotensin-
converting enzyme inhibitors, b-blockers, calcium channel
blockers, a-blockers, central agonists, and vasodilators).
Postdialysis BP
Postdialysis SBP. Patterns of associations with survival
were comparable to those for predialysis SBP, but the lowest
risk levels were (as expected) shifted lower than for
predialysis SBP (Figure 7a and b). For patient-level SBP,
mortality risk was elevated for patients with low (o110 or
120 mm Hg) but not high SBP levels. For facility-level SBP,
mortality risk was lowest at 120–139 mm Hg.
Postdialysis DBP. Mortality risk was lowest at
70–99 mm Hg (patient level) and 70–89 or 70–99 mm Hg
(facility level; Figure 8a and b).
Subgroup analyses
Subgroups studied were: with or without heart failure,
diabetes, and CV disease; serum albumin o or X3.8 g/dl;
ESRD duration o or X180 days; or use of any antihyper-
tensive medication (yes/no). Findings were consistent across
subgroups for analyses of patient-level and facility-level SBP.
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Figure 3 |Predialysis systolic blood pressure (SBP) and
mortality (fully adjusted model). (a) Mortality by patient-level
predialysis SBP categories (fully adjusted). (b) Mortality by facility-
level predialysis SBP categories (fully adjusted). A total of 24,525
hemodialysis patients from 920 facilities in Dialysis Outcomes and
Practice Patterns Study (DOPPS) I–III with end-stage renal disease
duration of 4180 days, excluding patients with predialysis SBP
o110mmHg. Cox models were stratified by geographic region
and study phase, accounting for facility-clustering effects, and
adjusted for all demographics, comorbid conditions, and labs
listed in Table 1. Facility-level analyses were adjusted additionally
for five facility practices. For this and subsequent figures, vertical
lines represent 95% confidence intervals (CIs). HR, hazard ratio.
*0.01pPo0.05; **0.001pPo0.01; ***Po0.001.
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Figure 4 |Predialysis diastolic blood pressure (DBP) and
mortality (fully adjusted model). (a) Mortality by patient-level
predialysis DBP categories (fully adjusted). (b) Mortality by facility-
level predialysis DBP categories (fully adjusted). A total of 25,424
hemodialysis patients from 919 facilities in Dialysis Outcomes and
Practice Patterns Study (DOPPS) I–III with end-stage renal disease
duration of 4180 days, excluding patients with predialysis
DBP o50mmHg. Cox models are as described for Figure 3.
*0.01pPo0.05; ***Po0.001. CI, confidence interval; HR, hazard ratio.
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Change in BP from before to after dialysis
The distribution of change in SBP from before to after dialysis
(pre minus post) was: 25th percentile¼ 0 mm Hg, 50th
percentile¼ 11 mm Hg, and 75th percentile¼ 25 mm Hg. As-
sociations of SBP with mortality were similar for patients with
change in SBP above versus below median value (12 mm Hg) in
both patient- and facility-level models. No interaction effect
was found between predialysis SBP and change in SBP (pre- to
post-HD) in patient- or facility-level model (P40.05).
DISCUSSION
The finding (Figure 3a) of elevated mortality for HD patients
with predialysis SBP o130 mm Hg, but not for patients with
uncontrolled HTN, is consistent with most prior observa-
tional findings of elevated mortality rates at low, not high, BP.
Interpretation of results from observational studies has been
complicated because BP level among HD patients tends to be
correlated with confounders (Table 1). This imbalance in
health status may potentially bias the association between BP
and death rates.5 The Dialysis Outcomes and Practice Patterns
Study (DOPPS) collects an extensive list of comorbidities,
laboratory values, medications, and clinical events, and our
multivariable analyses adjust for numerous potential con-
founders. Nonetheless, as this analysis relies exclusively on
measured patient-level data, it remains subject to bias due to
unmeasured patient characteristics affecting BP and health
status (that is, unmeasured confounders). Some examples of
information typically not captured completely in the medical
records (and therefore not in our analyses) include informa-
tion about the severity, chronicity, disability, functional status,
and psychosocial impact of diagnosed comorbidities, and the
patient’s ability to cope with ESRD and other conditions. In
general, predicting the direction of bias from hypothetical
confounders such as these is difficult.14
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Figure 5 |Predialysis systolic blood pressure (SBP) and mortality (stepwise adjustment). (a) Mortality by patient-level predialysis SBP
categories (stepwise adjustment). (b) Mortality by facility-level predialysis SBP categories (stepwise adjustment). A total of 24,525 patients,
as described for Figure 3. aAdjusted for demographics in Table 1; badjusted for demographics, comorbid conditions, and labs in Table 1. For
the facility-level SBP model, adjustment additionally for facility practices altered the hazard ratio (HR) slightly (not shown). *0.01pPo0.05;
**0.001pPo0.01; ***Po0.001. CI, confidence interval.
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To potentially lessen bias due to unmeasured patient
characteristics, we chose analysis of practice patterns at the
dialysis facility level, relating patient-level mortality to the
fraction of patients in each BP category at each dialysis
facility, rather than observed BP level for each patient. This
approach is a straightforward extension of the single
grouped-treatment method.15 In their results, Johnston
et al.15 noted that the bias resulting from grouped treatment
appears to be much smaller than that resulting from standard
analyses using individual treatment variables. Our analysis
avoids ‘ecologic bias’16,17 because it incorporates patient-level
outcome and covariate data. The method also has similarities
to instrumental variable (IV) analysis (and we performed a
supplementary IV analysis that corroborated the facility-level
BP findings).18–23 Recent applications of IV analysis in clinical
medicine have been published.24–29
Our analytic approach takes advantage of the ‘quasi-
random’ assignment of patients to different treatment
strategies at different facilities, based on the reasonable
assumption that differences in observed BP levels between
facilities are due in part to differences in provider BP
treatment protocols or preferences. In support of the validity
of this assumption, we observed large variation between
facilities in the percentage of patients at high and low SBP
levels (Figure 1b). We also found that facility target SBP is
associated with patient-level SBP (in a subset of DOPPS III
facilities with these data available, P¼ 0.003); that is, provider
preference influences achieved BP levels. Additionally, we
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Figure 6 |Predialysis diastolic blood pressure (DBP) and mortality (stepwise adjustment). (a) Mortality by patient-level predialysis DBP
categories (stepwise adjustment). (b) Mortality by facility-level predialysis DBP categories (stepwise adjustment). A total of 25,424 patients,
as described for Figure 4. aAdjusted for demographics in Table 1; badjusted for demographics, comorbid conditions, and labs in Table 1. For
the facility-level DBP model, adjustment additionally for facility practices altered the hazard ratio (HR) slightly (not shown). *0.01pPo0.05;
**0.001pPo0.01; ***Po0.001. CI, confidence interval.
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observed that patient health status is more nearly, although
imperfectly, balanced when we categorize patients according
to a facility-level measure of achieved BP levels (for example,
fraction of patients at SBPX160 mm Hg) versus according to
each patient’s individually achieved BP (Supplementary Table
A online).
We found that, on average, patients treated at facilities
with a higher proportion of patients at predialysis SBP
130–159 mm Hg have longer survival. A causal interpretation
of this association (based on motivation for the analysis of
facility practice) is that treatment to predialysis SBP
130–159 mm Hg leads to longer survival. However, as in
any clinical study, the potential for alternative explanations
merits consideration.
In particular, the observed differences in survival accord-
ing to facility-level BP may be because of other differences
between facilities (for example, a ‘good/bad facility’ effect).
Our analysis controls for facility achievement of widely
accepted (KDOQI) clinical practice guidelines (Figure 3b),
and hence the observed association is not explained by
achievement of these metrics of good practice. Nonetheless,
we cannot rule out facility-level confounding (that is,
unmeasured or incompletely specified facility-level variables
that can influence both BP levels and mortality) as an
alternative explanation for our findings. Stated in clinical
terms, better survival in facilities with more patients at
predialysis SBP 130–159 mm Hg may not be because of BP
control, but due to other practices more common in these
facilities that we did not account for analytically. Examples
include specific BP treatments, achievement of other
‘standard of care’ clinical practices, or generally higher
quality care that may occur in facilities with more patients in
the SBP 130–159 mm Hg range. Future studies to confirm or
refute this possibility are indicated.
In the absence of definitive clinical trial data, our findings
help clarify understanding of optimal BP on dialysis. At high
BP, facilities with more patients at predialysis SBP
X160 mm Hg have elevated mortality. This finding (assum-
ing a causal interpretation) contrasts with other observa-
tional studies in HD reporting no increased mortality at
elevated predialysis SBP in this range or higher.5,8–13 It is
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Figure 7 |Postdialysis systolic blood pressure (SBP) and
mortality (fully adjusted model). (a) Mortality by patient-level
postdialysis SBP categories (fully adjusted). (b) Mortality by
facility-level postdialysis SBP categories (fully adjusted). A total of
24,303 hemodialysis patients from 915 facilities in Dialysis
Outcomes and Practice Patterns Study (DOPPS) I–III with end-
stage renal disease duration of 4180 days, excluding patients
with postdialysis SBP o100mmHg. Cox models are as described
for Figure 3. *0.01pPo0.05; **0.001pPo0.01; ***Pp0.001.
CI, confidence interval; HR, hazard ratio.
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Figure 8 |Postdialysis diastolic blood pressure (DBP) and
mortality (fully adjusted model). (a) Mortality by patient-level
postdialysis DBP categories (fully adjusted). (b) Mortality by
facility-level postdialysis DBP categories (fully adjusted). A total of
24,805 hemodialysis patients from 911 facilities in Dialysis
Outcomes and Practice Patterns Study (DOPPS) I–III with end-
stage renal disease duration of 4180 days, excluding patients
with postdialysis DBP o50mmHg. Cox models are as described
for Figure 3. *0.01pPo0.05; ***Po0.001. CI, confidence interval;
HR, hazard ratio.
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consistent with well-established associations between HTN
and mortality in the general population,1–3 and with recent
studies challenging the notion that there is no association
between HTN and adverse outcomes among HD patients.30–34
Two meta-analyses of small clinical trials found that treatment
with antihypertensive medications was associated with longer
survival and fewer CV events.31,34 In contrast to our study,
these meta-analyses investigated antihypertensive medication
use, not BP levels, although one study reported that the
association between medication use and better outcomes was
stronger among patients with HTN.
At low BP, this analysis found higher mortality among
patients with SBP o130 mm Hg, and at facilities with more
patients at SBP o130 mm Hg. The finding of elevated risk at
low BP is consistent with prior observational analyses of HD
patient, and several possible explanations merit discussion.
First, could excess mortality at low BP be because of patient
health status alone? It is unlikely, as adjustment for
comorbidities (such as coronary heart disease and heart
failure) had little effect on associations between SBP and
mortality at the low SBP end (Figure 5a and b). An analysis of
facility BP practice further reduces the likelihood that excess
mortality at low BP levels is due to unmeasured patient
characteristics (such as illness severity).
Instead, our findings generally support the possibility that
low predialysis SBP may cause mortality. Management of
hemodynamic status in dialysis patients has unique con-
siderations, and treatment of some HD patients to the general
population’s optimal BP range may be dangerous. One likely
reason is hemodynamic instability during HD sessions. Recent
publications demonstrated cardiac regional wall motion
abnormalities and impaired myocardial blood flow during
dialysis by cardiac positron emission tomography scan.35,36
These findings add to historical observations of ST segment
abnormalities on electrocardiogram monitoring and eleva-
tions of troponin during HD. Repeated intradialytic ischemia,
often subclinical, leads to myocardial stunning and hiberna-
tion, which can cause remodeling, scarring, heart failure, and
arrhythmias, increasingly recognized as important causes of
death in HD patients.37,38 In this study, the association of low
predialysis SBP with elevated mortality was not modified by
change in SBP from before to after dialysis, but this variable
may be insensitive to intradialytic hypotension or hemody-
namic compromise during dialysis. Although our study did
not collect data on intradialytic BP levels, another study of
1244 patients showed that intradialytic hypotension asso-
ciated strongly with elevated mortality risk over 2 years.39
The optimal predialysis SBP range (130 to 159 mm Hg)
may be higher than expected because it represents the peak of
the 48- to 72-h dialysis cycle and overestimates the average
BP. This is supported by our analyses identifying lowest risk
postdialysis SBP (Figure 7a and b) 10–20 mm Hg lower than
for predialysis SBP (Figure 3a and b). A recent study found
an average interdialytic increase in SBP of 13 mm Hg by
ambulatory BP monitoring and 18 mm Hg by standard home
BP monitoring.40 Additionally, clinicians often instruct HD
patients to withhold predialysis doses of antihypertensive
medications. This practice would exacerbate overestimation
of optimal BP caused by relying on predialysis measurement.
The finding of a lower-limit optimal SBP value is
consistent with recent data in nondialysis populations. The
ACCORD study, a clinical trial of patients with type 2 diabetes
at high CV risk, found that targeting SBP o120 mm Hg
versus o140 mm Hg (achieved SBP 119 vs. 134 mm Hg) did
not reduce composite fatal and nonfatal major CV events.41 In
2009, the European Society of Hypertension raised concerns
that excessive BP lowering may increase the rate of coronary
events in patients at high CV risk, possibly because of
impairment of autoregulatory mechanisms that ensure organ
perfusion.42 They recommended target SBP 130–139 mm Hg
rather than a single cut-point value for higher-risk patients
receiving antihypertensive therapy.
Our findings indicate that management of DBP may be less
important than SBP. The risk for DBP in the adjusted model
(Figure 4) was lowest at 60–99 mm Hg, that is, across
the range of commonly observed DBP levels. Only 14%
of patients had predialysis DBP outside the range; 53% of
patients had predialysis SBP outside the lowest-risk range
of 130–159 mm Hg. Thus, the opportunity for improving
outcomes by modifying current practice is greater for SBP.
Adjustment for demographics (especially age) and comorbid-
ities had greater effect on the association with outcomes for
patient-level DBP than SBP (Figures 5a and 6a). Ventricular
stiffness in older patients and in hypertrophic cardiomyo-
pathy (common among dialysis patients)43 may explain much
of the association of lower DBP with elevated mortality.
Additionally, the following points may be noted regarding
our study. (1) Because the DOPPS patient sample is a random
cross-section of patients at participating HD units, this study’s
findings can be generalized to the variety of patients seen and
BP management decisions encountered on rounds in the
dialysis unit; (2) The study informs mortality risks over the
entire BP range in dialysis patients, unlike a randomized
controlled trial. (3) Our findings based on observed facility-
level BP values inform understanding of the association
between target BP and outcomes to the extent that variations
in facility-aggregated observed BP reflect differences between
facility BP targets. (4) Our study is not intended to compare
specific treatments (for example, volume management and/or
pharmacotherapy) for BP management.31,32,34,44 (5) Last, we
studied BP levels measured in the dialysis center to inform
current practice for most HD patients. Interdialytic BP
monitoring such as home BP monitoring has promise as a
future treatment target, but its practice is uncommon and may
not be feasible in many patients.45–48
Conclusion
Survival is significantly better among patients with pre-
dialysis SBP X130 mm Hg, and at facilities with more
patients at predialysis SBP 130 to o160 mm Hg. Opportu-
nities for improving outcomes may be greater for
treatment of SBP than DBP. The finding of elevated mortality
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among facilities with more patients at high SBP, if indicative
of a causal link between HTN and poor outcomes, clarifies
apparently contradictory results from prior observational
studies in HD patients versus clinical trials in the general
population. Elevated mortality at low SBP, in both our patient
and facility BP models, is consistent with prior studies of
dialysis patients and emerging concerns about excessive BP
lowering in nondialysis patients at high CV risk. It
corroborates accumulating evidence from clinical studies in
dialysis that myocardial stunning, associated with intradialytic
hypotension, may be common and is likely harmful. Although
additional investigation is indicated, these findings contrast
with opinion-based KDOQI BP targets, providing guidance
on optimal BP range in the absence of definitive clinical trial
data in the near future.
MATERIALS AND METHODS
Data source and study patients
The DOPPS is a prospective cohort study of HD practices and
patient outcomes. Study sampling plan and methods have been
described.49,50 Data were from DOPPS I (1996–2001), II (2002–2004),
and III (2005–2008). There were 38,511 adult (X18 years of age) HD
patients with predialysis SBP measurement reported at study entry,
randomly selected from 928 dialysis facilities: 308 facilities in DOPPS
I (n¼ 15,473 patients from France, Germany, Italy, Japan, Spain,
United Kingdom, and United States), 321 facilities in DOPPS II
(n¼ 12,311 patients from DOPPS I countries, plus Australia,
Belgium, Canada, New Zealand, and Sweden), and 299 facilities in
DOPPS III (n¼ 10,727 patients from the same 12 countries).
Detailed case-mix and comorbid data were collected for each patient
at study entry. Longitudinal laboratory values, medication data, and
cause-specific mortality events were collected during study follow-
up. Informed patient consent was obtained as indicated in
accordance with local requirements.
For primary analyses, patients with predialysis SBP
o110 mm Hg were excluded on the rationale that SBP o110 is
generally because of substantial comorbid illness, that is, SBP is not
treated to this level and is not reflective of provider practice. A
sensitivity analysis including patients with SBP o110 mm Hg is
presented. Patients from six facilities with less than seven patients
with recorded BP levels were excluded. For primary analyses of
prevalent HD patients, 25,907 patients from 922 facilities had ESRD
4180 days at DOPPS enrollment. Of these, 24,525 patients from
920 dialysis facilities had predialysis SBP X110 mm Hg at study
entry (used for primary analyses). The 10th, 50th, and 90th
percentiles for the number of patients per facility were 17, 26, and
37, respectively.
Outcomes and exposures
The primary outcome was mortality. In Cox regression models, time
at-risk was from study entry until death; study departure because of
kidney transplant, change in dialysis modality, or transfer to another
facility; or the end-of-study follow-up.
In DOPPS I and II, the three most recent BP measurements over
1 week on or before study enrollment were reported; the median value
was used. In DOPPS III, only the most recent measurement was
reported. The primary exposure was predialysis (that is, measured in
the HD unit before the start of a dialysis session) SBP level at DOPPS
enrollment (‘baseline’). For analyses of patient-level SBP, patients were
classified into 7 10 mm Hg SBP groups, from 110–119 to
170–179 mm Hg, and X180 mm Hg (with each patient in one of
seven SBP categories). For analyses of facility-level SBP, we created
seven continuous variables representing the proportion of patients in
each facility that were in each of the seven SBP categories. The seven
facility-level variables were assigned to all patients in that facility. Based
on results with seven categories, we performed additional analyses with
predialysis SBP levels divided into three categories: 110–129, 130–159,
and X160 mm Hg. Associations of predialysis DBP, postdialysis SBP,
and postdialysis DBP with mortality are also presented.
Statistical analysis
Distributions of patient-level and facility-level predialysis SBP and
DBP were depicted graphically. To examine cross-sectional associa-
tions of baseline patient characteristics with patient-level and
facility-level SBP, separate linear mixed and logistic models with
patient baseline characteristic as outcome and an ordinal variable of
BP category as predictor were used.
Cox regression was used to assess the association between all-
cause mortality (patient level) and exposure variables: (1) patient-
level SBP at baseline (each patient in one of seven SBP categories)
and (2) facility-level SBP (the proportion of facility patients in each
SBP category for all patients in the facility). The facility-level
approach is an extension of the single grouped-treatment method.15
Only 6 of 7 facility-level SBP categories (excluding 130–139 mm Hg)
were included to avoid linear dependence (that is, 6 proportions
do not add up to 1). Facility-level results were reported as HRs at
facilities with 20% more patients in a nonreference SBP category,
and correspondingly fewer patients in the reference category. We
divide both coefficient and standard error of the Cox regression
in the facility-level analysis by a factor of 5 to obtain the magnitude
of the association corresponding to every 20% of facility patients,
but the significance level and qualitative interpretation of the results
stay unchanged whether reported for 20% or, for example, 10% or
100% of facility patients.
Cox models were stratified by geographic region and study
phase, accounted for facility-clustering effects, and adjusted
sequentially for potentially confounding variables (Table 1). Facil-
ity-level analyses were further adjusted for five facility practices,
including percent of patients in guidelines for hemoglobin, serum
albumin, serum phosphorous, single pool Kt/V, and percent of
patients using a catheter for dialysis. Robust variance estimates
(sandwich estimator) were used to account for facility-level
clustering.46 Proportionality of hazards was confirmed graphically
and by an interaction term between each covariate and log-
transformed follow-up time. For missing data, missing indicators
were used. In confirmatory analyses, multiple imputation of missing
data was performed using IVEware (Ann Arbor, MI), and mortality
analyses were repeated using the imputed data.
In support of analyses of facility-level BP, supplemental analyses
used instrumental variable analysis with facility indictors as the
instrument.18,19,51,52 A linear-Cox IV approach was used, with
similarities to the traditional two-stage least-square IV method,
using a linear approximation in the first stage and Cox regression in
the second stage.24,25,53 Analyses used SAS 9.2 (SAS Institute, Cary,
NC). The authors followed STROBE Statement guidelines for
reporting observational studies.54
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